Tracer library / [225Ac]Ac-SibuDAB

[225Ac]Ac-SibuDAB

Also written as [Ac-225]Ac-SibuDAB

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Prostate cancer Dosimetry and biodistribution studies PSMA-directed radioligand therapy

What it is

Compound class: albumin-binding PSMA-targeted radioligand ((S)-ibuprofen-diaminobutyric acid-PSMA)
Target / mechanism: Prostate-specific membrane antigen (PSMA) PMID 40473466
Clinical application: Prostate cancer patients, heavily pretreated including prior 177Lu-PSMA therapy PMID 40473466
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer Patients.
2025 · J Nucl Med · Retrospective

Need this precursor?We can point you to suppliers for [225Ac]Ac-SibuDAB, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 30 (2026-09-18): Stage was 'investigational'; normalised to 'Clinical research', original wording kept here.